2011 Scrip 100: Taking drug regulation to a higher level
This article was originally published in Scrip
The regulation of drug development is moving to a new level, driven by advances in science and the need to better assess the safety profile of new compounds. Regulators will soon be faced with products emerging from areas such as regenerative medicine, gene therapy, personalised or stratified medicine, and nanotechnology. Finding new tools to assess safety, efficacy and quality is vital if these discoveries are to be translated into commercial products.
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?
In addition to our daily in-depth coverage of key events relating to the COVID-19 pandemic, we’re bringing you a periodic round-up of other developments. This edition covers Europe and other countries.